Tumor-associated trypsin inhibitor.
Tumor-associated trypsin inhibitor (TATI) is a low-molecular-weight (6 kDa) trypsin inhibitor that has been used as a marker for ovarian cancer. It is also expressed together with tumor-associated trypsin by many other tumors, and increased serum concentrations of TATI occur in connection with these. TATI is a prognostic marker for ovarian, bladder, and kidney cancer, which may be associated with the participation of trypsin in protease cascades contributing to tumor invasiveness.
Stenman
Ulf-Håkan
UH
Department of Clinical Chemistry, Helsinki University Central Hospital, Biomedicum, PB 700, FIN-00029 HUS, Finland.
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000175:diagnosis; D010940:Plant Proteins / Q000032:analysis* / Q000097:blood / Q000652:urine; D011379:Prognosis; D012016:Reference Values; D014361:Trypsin Inhibitors; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis; D000516:alpha-Amylases / Q000037:antagonists & inhibitors
D014408:Biomarkers, Tumor; D010940:Plant Proteins; D014361:Trypsin Inhibitors; D000516:alpha-Amylases